Originally published August 2025. Updated June 2026 with the full webinar video, clearer patient guidance, revised pathway context and supporting precision medicine resources.

Cholangiocarcinoma Australia Webinar Review 2025: Genomics, Guidelines and Treatment Pathways

This cholangiocarcinoma Australia webinar review explains why genomic profiling, national treatment pathways and earlier patient action now matter for bile duct cancer care in Australia.

Cholangiocarcinoma, also known as bile duct cancer, is rare, complex and often diagnosed late. For many patients, the problem is not only the cancer itself. The problem is timing. The right test may be ordered too late. The biopsy sample may not be strong enough. A targetable mutation may be found after the patient is already too unwell. A treatment or clinical trial may exist, but not be reached in time.

That is the gap this webinar addressed.

In January 2025, Cholangiocarcinoma Foundation Australia hosted a national clinician webinar focused on cholangiocarcinoma genomics, guidelines and the standardisation of Australian treatment pathways. The session brought together 142 clinicians and 28 industry experts and specialists, with presentations from Professor David Thomas, Professor John Zalcberg and Professor Juan Valle.

The webinar has now been published as a full video and can be watched below.

Watch the Full Webinar

Update on MoST / CaSP-Specific Cholangiocarcinoma Data and Standardisation of Australian Treatment Pathways.

This webinar features Professor David Thomas, Professor John Zalcberg and Professor Juan Valle discussing cholangiocarcinoma genomic profiling, MoST/CaSP data, matched therapy and the standardisation of Australian treatment pathways.

Why This Webinar Matters

Think of cholangiocarcinoma care like trying to repair a damaged bridge while traffic is still moving across it. The engineers need to know exactly where the damage is, what materials have failed, how much time they have, and which tools can still reach the site. In cancer care, that means diagnosis, staging, biopsy quality, genomic profiling, treatment selection, clinical trial matching and timing all have to work together.

If one part is delayed, the whole response can weaken.

This webinar showed that cholangiocarcinoma care is moving into a new stage. The science is no longer only asking, “What type of cancer is this?” It is now asking, “What is driving this cancer, what treatment might match it, and how do we make sure patients reach that option early enough?”

What the Webinar Covered

The session focused on four linked questions:

  • What does Australian genomic data now show about cholangiocarcinoma and biliary tract cancer?
  • How often are targetable mutations being found?
  • Why are too few patients receiving matched therapy?
  • How can Australian treatment pathways become more consistent, faster and fairer?

These questions matter because cholangiocarcinoma is not a simple single-path disease. It can involve different locations, different biological drivers, different mutations and different treatment opportunities. A patient’s options can change depending on whether the cancer is intrahepatic, perihilar, distal, gallbladder-related or part of the broader biliary tract cancer group.

That is why pathway discipline matters.

Speaker Highlights

Professor David Thomas: Real-World Genomic Insights from MoST and CaSP

Professor David Thomas, Founder and Chief Strategy Officer of Omico, presented real-world genomic insights from Australian patients with biliary tract cancer.

The key message was direct: genomic profiling is finding useful information, but the system is not yet moving fast enough to turn every finding into a treatment opportunity.

Professor Thomas presented updated data from 606 patients with biliary tract cancer. The key points included:

  • 60% of patients had a targetable genetic mutation.
  • Only 15% received matched therapy through a clinical trial, private access, PBS access or compassionate access.
  • The major barriers included late testing, poor sample quality, delayed turnaround times and treatment access gaps.

For patients and caregivers, the simple meaning is this: genomic profiling can identify possible treatment pathways, but it must be done early enough and with a good enough sample for the result to be useful.

A genomic result is not just information. It can become a doorway. But only if the patient reaches it in time.

Professor John Zalcberg: National Guidelines and Quality Measurement

Professor John Zalcberg, Head of the Cancer Research Program at Monash University, addressed the need for national consistency in cholangiocarcinoma and biliary tract cancer care.

The issue is not simply whether good care exists in Australia. It does. The issue is whether the same quality of care is available consistently across states, hospitals, regions and treating teams.

Professor Zalcberg discussed the absence of formal national cholangiocarcinoma-specific treatment guidelines in Australia and the work being done to review existing international guidelines, identify areas of variation, and develop quality indicators that may support a future national registry.

Key areas included:

  • Biopsy timing and biopsy quality.
  • Stenting decisions.
  • Molecular testing pathways.
  • Multidisciplinary review.
  • Eligibility for advanced options, including transplantation in selected circumstances.
  • Quality indicators that could help measure whether care is being delivered consistently.

For patients, this matters because variation creates risk. One patient may receive early molecular testing and specialist review. Another may not. One patient may be discussed by a specialist multidisciplinary team. Another may move through the system without the same level of cholangiocarcinoma-specific attention.

Guidelines do not cure cancer by themselves. But they reduce random variation. They help make sure important steps are not missed.

Professor Juan Valle: Emerging Treatment Options and Molecular Profiling at Diagnosis

Professor Juan Valle, Chief Medical Officer of the Cholangiocarcinoma Foundation USA, gave a global treatment perspective, particularly beyond first-line therapy.

The major message was that cholangiocarcinoma treatment is changing. Chemotherapy remains important, but targeted therapies and immunotherapy have become critical for selected patients.

Professor Valle highlighted the importance of identifying mutations and biomarkers early, including:

  • IDH1
  • FGFR2
  • HER2
  • BRAF
  • KRAS
  • MSI-high status
  • TMB and other genomic markers where relevant

The practical message for patients is simple: do not wait until the cancer has already moved through several treatments before asking about molecular profiling. The earlier the disease is understood, the more likely the treating team can preserve future options.

In cholangiocarcinoma, the sequence matters. Diagnosis first. Staging. Specialist review. Good tissue sample. Genomic profiling. Treatment plan. Clinical trial search. Monitoring. Re-biopsy or ctDNA testing when the disease changes.

This is how options are kept open.

The Central Problem: The Science Is Moving Faster Than the System

The strongest theme across the webinar was that cholangiocarcinoma knowledge has advanced, but patient access has not caught up.

That creates a survival gap.

The biology may reveal a target. The treatment may exist. A clinical trial may be available. But if testing is late, the sample fails, referral is delayed, or the treating pathway is unclear, the patient can still miss the option.

This is why Cholangiocarcinoma Foundation Australia focuses on response, not awareness alone.

Awareness says, “This cancer exists.”

Response asks, “What must happen next, in what order, and how do we make sure the patient does not lose time?”

What Patients and Caregivers Should Take From This Webinar

This webinar was hosted for clinicians, specialists and industry experts, but the lessons are highly relevant for patients and caregivers.

If you or someone you love has been diagnosed with cholangiocarcinoma or bile duct cancer, the key message is not to panic or try to understand everything at once. The key is to follow the process.

1. Confirm the Exact Diagnosis

Cholangiocarcinoma can be intrahepatic, perihilar or distal. It may also overlap with gallbladder cancer, pancreaticobiliary cancers or other upper gastrointestinal cancers. The exact diagnosis affects treatment planning.

Ask your team:

  • What exact type of cancer is this?
  • Where did it most likely start?
  • Is it intrahepatic, perihilar, distal or another biliary tract cancer?
  • Has the pathology been reviewed by a specialist gastrointestinal or hepatobiliary pathologist?

2. Ask About Genomic Profiling Early

Genomic profiling looks for the biological drivers inside the cancer. These may include mutations, fusions or other changes that can guide targeted therapy, immunotherapy or clinical trial options.

Ask your team:

  • Has comprehensive genomic profiling been ordered?
  • Is there enough tissue from the biopsy?
  • Which laboratory is doing the test?
  • When will the result return?
  • Will the result be reviewed by a molecular tumour board or precision oncology team?

3. Protect Tissue Quality

A biopsy is not just about proving cancer is present. In modern cholangiocarcinoma care, the tissue sample may also be needed for molecular testing.

If the sample is too small, damaged or poorly handled, the patient may lose the chance to identify a targetable mutation.

Ask:

  • Is the biopsy sample suitable for full genomic profiling?
  • If not, should another biopsy be considered?
  • Could ctDNA testing be useful if tissue is limited?

4. Seek Specialist Review Early

Cholangiocarcinoma is rare. Most clinicians will not see many cases. That does not mean they are poor doctors. It means the cancer is uncommon and benefits from specialist input.

Ask:

  • Has my case been reviewed by a hepatobiliary multidisciplinary team?
  • Should I seek a second opinion from a cholangiocarcinoma specialist?
  • Are there surgical, radiation, interventional radiology, targeted therapy or clinical trial options that should be considered now?

5. Search for Clinical Trials Before the Situation Becomes Urgent

Clinical trials are often time-sensitive. A patient may need to meet strict eligibility criteria. They may need certain blood results, performance status, mutation results or treatment history.

Waiting until all standard options are exhausted can mean the patient is no longer well enough to enter a trial.

Ask:

  • Are there clinical trials that match my diagnosis or mutation?
  • Should trial options be reviewed before starting the next treatment?
  • Could treatment choice now affect trial eligibility later?

Biology, Physiology and Patient Decisions

This webinar also shows why cholangiocarcinoma needs to be understood across three levels.

Biology: What Is Driving the Cancer?

Biology is the engine room. It asks what is happening inside the cancer cells. Are there mutations, fusions, immune markers or DNA repair problems that could guide treatment?

This is where genomic profiling matters.

Physiology: What Is Happening in the Body?

Physiology is the flow system. It asks how the cancer is affecting the bile ducts, liver, pancreas, blood tests, bile flow, infection risk, jaundice, weight, inflammation and treatment tolerance.

This is where stenting, drainage, liver function, biopsy quality and timing matter.

Cognition: What Decisions Must Be Made?

Cognition is the driver. It asks whether the patient and caregiver understand the next step clearly enough to act.

This is where patient response matters. Patients do not need to become scientists. But they do need to know what questions protect their options.

Foundation Perspective: From Knowledge to Response

For Cholangiocarcinoma Foundation Australia, this webinar confirms a central point: survival improves when the system responds earlier, smarter and more consistently.

The Foundation’s role is to help close the gap between what science now knows and what patients can access in time.

That work includes:

  • The Patient Navigator Journal — helping patients and caregivers organise records, understand key steps and prepare better questions.
  • The Mutational Translator — turning genomic reports into language patients and families can understand.
  • The Patient-Endorsed Medical Registry — helping patients identify clinicians with real cholangiocarcinoma experience.
  • The Second Opinion Project — helping patients access specialist review regardless of distance or postcode.
  • Clinical trial navigation — helping patients understand whether a mutation, treatment history or disease stage may connect to a trial opportunity.

The goal is not to replace the treating team. The goal is to help the patient reach the treating team with better information, better questions and fewer missed steps.

What This Means for Australian Cholangiocarcinoma Care

This cholangiocarcinoma Australia webinar review makes one thing clear: the future of bile duct cancer care will depend on coordinated execution.

Australia needs:

  • Earlier genomic profiling.
  • Better biopsy planning and tissue handling.
  • Clearer national treatment pathways.
  • Consistent multidisciplinary review.
  • Faster access to matched therapies.
  • Better clinical trial matching.
  • Patient education that helps people act before options are lost.

The treatment landscape is no longer static. New data, new drugs, new trials and new biomarkers are changing what may be possible. But possibility is not enough. Patients need access, timing and pathway discipline.

Trusted External Information

For broader context on cancer care pathways, genomic profiling and biliary tract cancer treatment guidance, readers may also wish to review:

Related Foundation Resources

If you are newly diagnosed or helping someone with cholangiocarcinoma, these Foundation resources may help you take the next step:

Final Patient Summary

This webinar showed that cholangiocarcinoma care in Australia is changing. Genomic profiling is finding targetable mutations. Matched therapies and clinical trials are becoming more important. National pathways and guidelines are needed so patients receive more consistent care. The key lesson for patients is simple: ask early, test early, seek specialist review early and keep options open before decisions become urgent.

Disclaimer

This article is provided for general educational and informational purposes only. It does not replace professional medical advice, diagnosis or treatment. Patients should always speak with their own qualified healthcare team before making decisions about testing, treatment, clinical trials or second opinions. Medical knowledge and treatment access may change over time.